• Online Features  This Article  • Full text  • PDF  • eTables  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (24)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Pediatrics  • Adolescent Medicine  • Psychiatry  • Adolescent Psychiatry  • Child Psychiatry  • Depression  • Psychopharmacology  • Suicide  • Quality of Care  • Patient Safety/ Medical Error  • Drug Therapy  • Adverse Effects  • Pediatric Dosing  • Alert me on articles by topic  Social Bookmarking   What's this?

Anne M. Libby, PhD; Heather D. Orton, PhD; Robert J. Valuck, PhD, RPh

Arch Gen Psychiatry. 2009;66(6):633-639. doi:10.1001/archgenpsychiatry.2009.46

Context  In October 2003 the Food and Drug Administration (FDA) issued a Public Health Advisory about the risk of suicidality for pediatric patients taking antidepressants; a boxed warning, package insert, and medication guide were implemented in February 2005. The warning was extended to young adults aged 18 to 24 years in May 2007. Immediately following the 2003 advisory, unintended declines in case finding and non–selective serotonin reuptake inhibitor substitute treatment were shown for pediatric patients, and spillover effects were seen in adult patients, who were not targeted by the warnings.

Objective  To determine whether the unintended declines in depression care persisted for pediatric, young adult, and adult patients.

Design  Time series analyses.

Setting  Ambulatory care settings nationally.

Patients  Pediatric, young adult, and adult cohorts of patients with new episodes of depression (n = 91 748, 70 311, and 630 748 episodes, respectively).

Interventions  Post–FDA advisory trends were compared with expected trends based on preadvisory patterns using a national integrated managed care claims database from July 1999 through June 2007.

Main Outcome Measures  Depression diagnosis; antidepressant, antipsychotic, and anxiolytic prescriptions; and psychotherapy visits.

Results  Changes in pediatric depression care were similar to changes for adults. National diagnosis rates of depression returned to 1999 levels for pediatric patients and below 2004 levels for adults. Primary care providers continued significant reductions in new diagnoses of depression (44% lower for pediatric, 37% lower for young adults, 29% for adults); diagnoses by mental health providers who were not psychiatrists increased. Numbers of prescriptions of anxiolytic and atypical antipsychotic medications did not significantly change from preadvisory trends. Psychotherapy increased significantly for adult, though not pediatric, cases. Selective serotonin reuptake inhibitor use decreased in all cohorts; serotonin-norepinephrine reuptake inhibitor increased for adults.

Conclusions  Diagnosing decreases persist. Substitute care did not compensate in pediatric and young adult groups, and spillover to adults continued, suggesting that unintended effects are nontransitory, substantial, and diffuse in a large national population. Policy actions are required to counter the unintended consequences of reduced depression treatment.

Author Affiliations: Schools of Public Health (Drs Libby and Orton) and Pharmacy (Dr Valuck), University of Colorado Denver, Denver.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

This Month in Archives of General Psychiatry
Arch Gen Psychiatry. 2009;66(6):579.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ten-Year Trends in Quality of Care and Spending for Depression: 1996 Through 2005
Fullerton et al.
Arch Gen Psychiatry 2011;68:1218-1226.
ABSTRACT | FULL TEXT  

Boxed warning inconsistencies between drug information resources and the prescribing information
Cheng et al.
Am J Health Syst Pharm 2011;68:1626-1631.
ABSTRACT | FULL TEXT  

Invited Commentary--Prescription Drug Label Adverse Events: A Call for Prioritization: Comment on "A Quantitative Analysis of Adverse Events and 'Overwarning' in Drug Labeling"
Cheng and Guglielmo
Arch Intern Med 2011;171:946-947.
FULL TEXT  

The 2004 FDA warning on antidepressant suicidality risk changed outpatient treatment patterns for young people with new-onset depression
Bridge and Kelleher
Evid. Based Ment. Health 2011;14:42-42.
FULL TEXT  

Current use of antiepileptic drugs is associated with an increased risk of suicidality in people with depression but not in people with epilepsy or bipolar disorder
Reid
Evid. Based Ment. Health 2011;14:3-3.
FULL TEXT  

National Trends in the Treatment for Depression From 1998 to 2007
Marcus and Olfson
Arch Gen Psychiatry 2010;67:1265-1273.
ABSTRACT | FULL TEXT  

Beware extrapolation from ecological data
Hammad and Mosholder
BMJ 2010;341:c6844-c6844.
FULL TEXT  

Are Adolescents Dying by Suicide Taking SSRI Antidepressants? A Review of Observational Studies
Dudley et al.
Australas Psychiatry 2010;18:242-245.
ABSTRACT | FULL TEXT  

The FDA's SSRI Warning: "We're from the Government, and We're Here to Help"?
JWatch Psychiatry 2009;2009:2-2.
FULL TEXT